Publication: CD5 as a prognostic marker in patients with diffuse large B-cell lymphoma: a multicenter study
Loading...
Program
KU-Authors
Organization Authors
Co-Authors
Demirci, Ufuk
Kirkizlar, Hakki Onur
Umit, Elif G.
Gursoy, Vildan
Pinar, Ibrahim Ethem
Ozkalemkas, Fahir
Guven, Zeynep Tugba
Kaynar, Leylagul
Karadag, Fatma Keklik
Saydam, Guray
Date
Language
Type
Embargo Status
N/A
Journal Title
Journal ISSN
Volume Title
Alternative Title
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL) and comprises a heterogeneous group of disease. While classification of B-cell lymphomas has been evolving to include clonality in a specific manner, morphology, and immunohistochemistry remain the backbone. We aimed to evaluate the value of CD5 expression on disease characteristics as well as prognosis in patients with DLBCL. Data of 131 patients with DLBCL with CD5 positivity and as a comparison arm, data of 129 patients with DLBCL without CD5 positivity were evaluated. Mean age was 59 and 55.7% of the patients were male. Overall survival was 29.8 months. Poor prognostic factors including (high-LDH levels, B symptoms, low ECOG score, high R-IPI and NCCN-IPI score) were observed to be significantly related with CD5 positivity. Mean survival in CD5 positive patients were 29.8 months, which is significantly shorter than the general DLBCL survival worldwide. CD5 expression shall be evaluated in all samples of DLBCL patients due to its possible effects on outcomes.
Source
Publisher
Springer Science and Business Media Deutschland GmbH
Subject
Citation
item.page.haspartof
Source
Journal of Hematopathology
item.page.ispartofseries
item.page.edition
DOI
10.1007/s12308-022-00523-6
item.page.datauri
item.page.link
Rights
N/A
Copyrights Note
Rights and licensing
N/A
